---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-016250"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:05:18.406688+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics enters ROCK2 inhibitor collaboration with Graviton; invests $10M for exclusive CNS rights

## Summary
- Ovid pays $10M upfront in Graviton Series A preferred stock for exclusive license to GV101 and other ROCK2 inhibitors.
- Royalties on net sales range from mid-teens to high-teens; no milestone payments are required.
- Initial focus: cerebral cavernous malformations and seizure disorders; GV101 is in Phase 1.
- Graviton conducts development through Phase 2; Ovid handles post-Phase 2 development and commercialization worldwide except China, Hong Kong, Macau, Taiwan.
- Ovid CEO Dr. Jeremy Levin will join Graviton's Board of Directors.

## SEC filing metadata
- accession: 0000950170-23-016250
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000095017023016250/0000950170-23-016250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000095017023016250/ovid-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-016250
- JSON: https://secwatch.observer/filing/0000950170-23-016250.json
- Plain text: https://secwatch.observer/filing/0000950170-23-016250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.